When treated with pembrolizumab 2 mg/kg, progression-free survival for patients with at least 50% of tumor cells expressing PD-L1 was greater than that with docetaxel (median 5.0 months vs. 4.1 months) and overall survival was also longer (median 14.9 months for pembrolizumab and 8.2 months for docetaxel).

In a review of data from the NLST, researchers sought to determine if a risk-targeting approach would more efficiently select high-risk persons for lung cancer screening than the eligibility criteria ...